Contact Us
Drug Search Results
More Filters [+]

Pegdinetanib

Alternative Names: pegdinetanib, ct-322, ct322, ct 322, bms-844203, bms844203, bms 844203, angiocept
Latest Update: 2024-05-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: VEGFR2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pegdinetanib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|Colorectal Cancer|Brain Stem Cancer|Glioblastoma

Phase 1: Glioblastoma|Oncology Solid Tumor Unspecified|Lymphoma, Non-Hodgkin

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CT322

P1

Withdrawn

Oncology Solid Tumor Unspecified

2015-01-01

2008-007768-41

P2

Completed

Non-Small-Cell Lung Cancer

2013-08-28

CA196-005

P2

Terminated

Non-Small-Cell Lung Cancer

2013-08-01

2008-006561-89

P2

Completed

Colorectal Cancer

2011-10-17

Recent News Events

Date

Type

Title

05/15/2024

PubMed

 Unraveling the Ties: Type 2 Diabetes and Parkinson's Disease - A Nano-Based Targeted Drug Delivery Approach.

05/07/2024

PubMed

 Biomimetic Nanovesicles as a Dual Gene Delivery System for the Synergistic Gene Therapy of Alzheimer's Disease.

04/25/2024

PubMed

 Enhancing glioma-specific drug delivery through self-assembly of macrophage membrane and targeted polymer assisted by low-frequency ultrasound irradiation.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions